Psilocybin for Migraine: What Early Studies Found

What the Research Examined

The findings summarized here come from several distinct early human studies, as reviewed in a WebMD article on psilocybin and migraines that draws on published research and expert commentary. The most frequently cited pilot enrolled 10 adults with migraine who each received a low oral dose of psilocybin across two treatment sessions. Participants self-reported migraine frequency and pain severity during a two-week follow-up window. The researchers noted no obvious differences by age, sex, or whether participants had episodic versus chronic migraine, though they acknowledged the sample was far too small to draw subgroup conclusions.

A second, much larger population study analyzed survey data from 11,251 individuals and looked for associations between lifetime use of classic psychedelics, including psilocybin and LSD, and self-reported experience of frequent bad headaches. People who reported any lifetime psychedelic use were approximately 25% less likely to report frequent bad headaches. Importantly, this is a correlational finding and does not establish that psychedelics caused the reduction. A third retrospective analysis examined 170 people across multiple headache diagnoses, including 63 with migraine and 44 with tension headache, who had used either a microdose, a full dose, or both. Participants in that analysis reported same-day pain reduction, with full doses outperforming microdoses and microdoses outperforming conventional migraine medication on self-reported relief. Researchers framing the broader picture of how psilocybin interacts with the brain’s serotonin system note that psilocybin is thought to act on serotonin receptors in a way that modulates, rather than simply activates or blocks, pain signaling, which may partly explain its effect on headache disorders.

Expert commentary in the review came from Kylie Gagan, a registered nurse and director of education for the Association of Migraine Disorders, and researcher Emmanuelle Schindler, MD, PhD. Gagan noted that the field is growing and that ongoing data collection through the 2025 Global Psychedelic Survey, covering 109 nations and 18 languages, will help researchers determine whether current trends hold at a larger scale. Schindler highlighted that, unlike mental health applications of psilocybin where a more intense psychedelic experience tends to correlate with better outcomes, migraine patients may achieve clinically meaningful relief at doses low enough to produce minimal perceptual effects.

What the Findings Show

Taken together, these early results point in a consistent direction: that psilocybin, even at low doses, may meaningfully affect migraine frequency and pain severity. But each study carries significant limitations. The pilot is too small to generalize. The population survey cannot establish causation, and self-reported psychedelic use and headache history are both subject to recall error. The retrospective analysis of 170 patients relied on participants self-selecting their dose and self-reporting outcomes outside a controlled setting. Researchers and clinicians quoted in the review consistently recommend that psilocybin for migraine be studied only within formal clinical trial settings until a larger body of controlled evidence exists.

Can psilocybin reduce migraine frequency or pain?

Early human studies suggest it may. A 10-person pilot reported fewer attacks and less severe pain after low-dose psilocybin, and a large survey found an association between psychedelic use and lower rates of frequent bad headaches. Researchers caution that much larger controlled trials are needed before drawing firm conclusions.

What This Is, and What It Is Not

Our Take

May love guide the hearts of all beings.Doug Red Hail Pineda, Founder